Released in the New England Journal of Medicine.

These data offer important insight into this medicine being developed for ladies with postmenopausal osteoporosis at high risk for fractures. In this Stage 2 trial, each of the five romosozumab dose regimens significantly increased BMD compared with pooled placebo groupings at the lumbar spine, total hip and femoral neck areas . The biggest increases were noticed with the romosozumab 210 mg once-monthly dose, with mean increases compared with baseline of 11.3 % at the lumbar spine, 4.1 % at the full total hip and 3.7 % at the femoral neck. Additionally, in exploratory analyses, BMD benefits were greater than energetic comparators at month 12 significantly, with romosozumab treatment achieving a mean increase of 11.3 % at the lumbar spine compared to increases of 4.1 % and 7.1 % at the same region accomplished with FOSAMAX and FORTEO, respectively.Retail pharmacy segment gross margin declined from 31.2 percent in fourth quarter 2009 to 27.1 percent this quarter, reflecting the acquisition of shops completed in 2010 2010 with inventories valued at market value rather than at price. Pharmaceutical manufacturing segment gross margin reduced from 71.1 percent in fourth quarter 2009 to 62.6 percent in this quarter due to marketplace penetration of lower profit products. Operating expenses increased by 49.3 percent to $4.7 million, compared to $3.1 million in the same period this past year. Administrative expenditures increased 55.7 percent to $2.8 million, or 4.2 percent of revenue, as compared to $1.8 million, or 4.9 percent of revenue, in the same period of 2009, primarily because of an increase in the incurrence of public business professional fees and increased share based compensation.